University of Pittsburgh, 1993, BS Pharmacy, Magna Cum Laude
University of North Carolina at Chapel Hill, 1995, PharmD
Dr. McCune’s research focuses on the clinical pharmacology of anticancer agents and immunosuppressants. Specifically, she has quantified the exposure of anticancer agents and immunosuppressants in hematopoietic cell transplant recipients used to treat malignant and non-malignant conditions. She is currently developing mathematical models to identify anticancer agent plasma exposure effective at treating cancer and modeling drug doses and dosing frequencies to optimize efficacy in pediatric cancer patients. Her work also evaluates constitutional pharmacogenomics relevant to drug exposure and drug response.
She has received several major National Institutes of Health grants for personalized medicine with children and adults with cancer, and has over 130 publications in her areas of interest. She has also served as a charter member of the NIH Developmental Therapeutics Study Section (September 2009-June 2013) and is a member of Children’s Oncology Group trials.
Dr. McCune has over 15 years of clinical research experience in oncology, predominantly in special populations - specifically hematopoetic cell transplant and pediatric cancer patients. I have lead a multi-discliplinary team of analytic chemists, study coordinators, and data managers to successfully conduct pharmacokinetic/dynamic studies in cancer patients.
Research Expertise: Clinical Pharmacology, Pharmacokinetics, Ancillary Biomarker Studies, Grant Writing & Reviewing, Pediatrics and Hematopoietic Cell Transplant.
1. “Pharmacogenetics of Cyclophosphamide ADRs in Children.” 1 R21 CA162059-01A2. September 2011-August 2014. Principal Investigator.
2. “Pharmacogenetics in children with high-risk neuroblastoma.” 1R03CA178104-01. September 2013-September 2015. Principal Investigator.
3. Ancillary Biomarker Studies to ANBL12P1: Melphalan Pharmacokinetics.” Cook Children’s Foundation. June 2013-May 2015. $25,000. Principal Investigator.
4. “Impact of bone metastasis and skeletal related events (SREs) upon survival in metastatic castration resistant prostate cancer.” April 2013-March 2015. Co-investigator. Principal Investigator: Scott D. Ramsey, MD, PhD, HICOR.
5. “Choosing Wisely: Colony-stimulating factors.” October 2013-September 2014. Co-investigator. Principal Investigator: Scott D. Ramsey, MD, PhD, HICOR.